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Background: The EphB4 receptor tyrosine kinase is overexpressed in many cancers including prostate cancer. The
molecular mechanisms by which this ephrin receptor influences cancer progression are complex as there are
tumor-promoting ligand-independent mechanisms in place as well as ligand-dependent tumor suppressive pathways.
Methods: We employed transient knockdown of EPHB4 in prostate cancer cells, coupled with gene microarray analysis,
to identify genes that were regulated by EPHB4 and may represent linked tumor-promoting factors. We validated target
genes using qRT-PCR and employed functional assays to determine their role in prostate cancer migration and invasion.
Results: We discovered that over 500 genes were deregulated upon EPHB4 siRNA knockdown, with integrin β8 (ITGB8)
being the top hit (29-fold down-regulated compared to negative non-silencing siRNA). Gene ontology analysis found
that the process of cell adhesion was highly deregulated and two other integrin genes, ITGA3 and ITGA10, were
also differentially expressed. In parallel, we also discovered that over-expression of EPHB4 led to a concomitant
increase in ITGB8 expression. In silico analysis of a prostate cancer progression microarray publically available in
the Oncomine database showed that both EPHB4 and ITGB8 are highly expressed in prostatic intraepithelial
neoplasia, the precursor to prostate cancer. Knockdown of ITGB8 in PC-3 and 22Rv1 prostate cancer cells in vitro
resulted in significant reduction of cell migration and invasion.
Conclusions: These results reveal that EphB4 regulates integrin β8 expression and that integrin β8 plays a hitherto
unrecognized role in the motility of prostate cancer cells and thus targeting integrin β8 may be a new treatment
strategy for prostate cancer.
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Erythropoietin-producing hepatocellular (Eph) Type-B
receptor 4 (EphB4) is part of the largest family of
membrane-bound receptor tyrosine kinases (RTK) which
consists of 14 different receptors which are classed as
EphA or EphB. Their ligands, the ephrins, are also cell
membrane-bound, either via glycosylphosphatidylinosi-
tol (GPI)-linkage (ephrin-A ligands) or transmembrane-
embedded (ephrin-B ligands). Interaction between Eph* Correspondence: s.stephenson@qut.edu.au
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article, unless otherwise stated.receptors and their ligands normally takes place in trans
through the binding of 2 ligands on one cell to 2 recep-
tors on an adjacent cell forming a heterotetramer that is
the basic complex required for signaling. EphB4 plays an
important role in cell signaling and is also involved in
regulating cell morphology, adhesion, migration and
invasion through modification of the cell’s actin cyto-
skeleton and by influencing the actions of integrins [1].
Moreover, depending on the cell-environment condi-
tions, EphB4 demonstrates the ability to be both a tumor
promoter, when over-expressed and in the absence of
stimulation by its sole cognate ligand, ephrin-B2, as well
as a tumor suppressor stimulated by ephrin-B2 [2-6].
EphB4 is overexpressed in 66% of prostate cancerCentral. This is an Open Access article distributed under the terms of the
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cancer development and progression [2,7]. It has been
shown using targeted siRNA sequences that knockdown
of EphB4 in prostate cancer causes a significant reduc-
tion in cell motility in vitro and tumor growth in vivo
[5]. However, the mechanisms by which removal of
EphB4 exerts these effects are largely unknown. To date,
no study has investigated the broader consequences
on gene expression of siRNA-mediated knockdown of
EPHB4 in prostate cancer. Therefore, we sought to
determine the genome-wide changes upon transient
knockdown of EPHB4 in a ligand-independent context
in the prostate cancer cell line LNCaP.
Through gene expression analysis following EPHB4
knockdown, validation of the microarray data, and
EphB4 over-expression, we have determined that EphB4
regulates the expression of integrin β8 in prostate cancer
cell lines.
Methods
Cell culture
All cell lines were purchased from the American Type
Culture Collection (Manassas, VA). LNCaP, PC3 and
22Rv1 prostate cancer cells were cultured in RPMI 1640
(Life Technologies, Mulgrave, VIC, Australia) supple-
mented with 10% fetal calf serum (FCS). EphB4 over-
expressing stable 22Rv1 cell lines, together with
vector-only (VO) and parental 22Rv1 cells, were gen-
erated as described previously [2].
siRNA transfection
Lipofectamine 2000 (Life Technologies) was used to
transiently transfect LNCaP cells with 10 nM of EPHB4
siRNAs (SI00288589, SI04435053; Qiagen, Chadstone,
VIC, Australia) or PC3 and 22Rv1 cells with 100 nM of
ITGB8 siRNAs (SI00034454, SI03066623, Qiagen). The
AllStars non-silencing negative control siRNA (Qiagen)
was used at the same concentration as gene-specific
siRNAs for all experiments. After 48 h, RNA from both
the siRNA-treated cells and the EphB4 over-expressing
cells was extracted using Trizol (Life Technologies).
Microarray gene expression profiling
Triplicate samples of EPHB4 siRNA knockdown and re-
spective control siRNA transfected LNCaP cells were ex-
tracted for RNA and prepared for microarray profiling,
which was performed on a custom Agilent 4 × 180 K
oligo array (VPCv3 ID:032034, GEO GPL16604, Agilent
Technologies, Mulgrave, VIC, Australia). This micro-
array contains the Agilent 44 K (ID:014850) probe set
incorporating human gene expression protein-coding
probes as well as non-coding probes; with the probes
targeting exonic regions, 3′UTRs, 5′UTRs, as well as in-
tronic and intergenic regions [8]. RNA was isolated withTrizol (Life Technologies), further purified using an
RNeasy Mini Kit (Qiagen) with DNAse treatment ac-
cording to the manufacturer’s protocol. RNA samples
were analyzed by a Bioanalyzer (Agilent) to ensure the
RNA was of high quality. RNA (100 ng) from each
group was amplified and labelled using the Low Input
Quick Amp Labeling Kit (Agilent) and the protocol for
One-Color Microarray-Based Gene Expression Analysis.
The input RNA was reverse transcribed into cDNA,
using an oligo-dT/T7-promoter primer which introduces
a T7 promoter region. The subsequent in vitro transcrip-
tion uses a T7 RNA polymerase, which simultaneously
amplifies target material into cRNA and incorporates
cyanine 3-labeled CTP. cDNA synthesis and in vitro
transcription were both performed at 40°C for 2 h. The
labelled cRNA was then purified with Qiagen’s RNeasy
mini-spin columns and quantified using a Nanodrop-
1000 (Thermo Scientific, Waltham, MA, USA). cRNA
(1650 ng) from each sample was loaded onto the 4x180
K custom microarray and allowed to hybridize at 65°C
for 17 h. The arrays were scanned using an Agilent
Microarray Scanner G2565CA.
Microarray data analysis
The microarray data were processed with Agilent Feature
Extraction Software (v10.7). A quantile between-array
normalization was applied and differential expression
was determined using an unpaired T-test, asymptotic
p-value and a 2-fold cut-off (GeneSpring GX11, Agilent
Technologies). The gene expression levels are presented as
fold change. Genes that were significantly different be-
tween two groups were identified with a p value of < =0.05,
and an average fold change of > = 2.
Normalized gene expression data of the experiment are
Minimum Information About a Microarray Experiment
(MIAME) and have been submitted to Gene Expression
Omnibus (GEO) with the accession number GSE61800.
Quantitative real-time PCR
Extracted RNA was reverse transcribed using Superscript
III reverse transcriptase according to the manufac-
turer’s instructions (Life Technologies). Quantitative
RT-PCR for EPHB4 expression was performed in
triplicate using a TaqMan Gene Expression Assay
(EPHB4: Hs00174752_m1 Life Technologies) and TaqMan
Universal PCR Master Mix, No AmpErase UNG (Life
Technologies) on a Rotor-Gene 6000 (Qiagen). The en-
dogenous reference gene hydroxymethylbilane synthase
(HMBS: Hs00609297_m1) was used for normalization
and results are expressed as the EPHB4:HMBS ratio.
For integrin gene expression analysis the SYBR Master
Mix (Life Technologies) was used with GAPDH as a
housekeeping gene. Primer sequences are listed in
Table 1.
Table 1 Primer sequences for semi-quantitative RT-PCR and qRT-PCR
Gene Forward primer 5’ to 3’ Reverse primer 5’ to 3’ Product size (bp)
ITGA3 AGCGCTACCTGCTCCTGGCT GGGCAGTGAGTGGGCACAGG 99
ITGA10 CTGACAGGTCTCTGCTCCCCC CCATCGCTGTCCACCCCCAA 120
ITGB8 TGTGTGCTGGGCATGGAGAGTGT CAGTGCTGGGCTGCTGCTGAA 100
ITGAV CATCTGTGAGGTCGAAACAGG TGGAGCATACTCAACAGTCTTTG 137
EPHB4 TCAATGTCACCACTGACCGAGAGGTA GGTATTTGACCTCGTAGTCCAGCACA 141
GAPDH CTGCACCACCAACTGCTTAG GTCTTCTGGGTGGCAGTGAT 108
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RT-PCR analysis was carried out using standard condi-
tions with primers as shown in Table 1). PCR conditions
were as follows: initial denaturation 94°C for 15 min
then 94°C for 30s; 60°C for 30s; 72°C for 30s repeated
35 times, final elongation 72°C for 10 min. PCR products
were analyzed on a 2% Tris-acetate agarose gel contain-
ing 0.01% ethidium bromide and photographed using a
Gel doc system (Syngene, MD, USA).
SDS-PAGE and western blotting
Cells were lysed with ice-cold RIPA buffer (50 mM Tris
pH 7.4, 1% Triton X-100, 0.5% sodium deoxycholate,
150 mM NaCl, 2 mM EDTA, 1 mM sodium orthova-
nadate, 1 mM NaF, 1 mM PMSF, 10 μg/ml aprotinin)
supplemented with protease inhibitors (Complete
Mini-EDTA-free tablets; Roche, Castle Hill, NSW,
Australia). Protein lysates were mixed at 4°C for
15 min, then insoluble proteins removed by centrifu-
gation at 14,000 rpm. Protein concentrations were
determined using the BCA Protein Assay Kit (Pierce,
Rockford, IL, USA). Protein samples (20-50 μg) were
separated on SDS-PAGE gels (4% stacking and 10%
separating) before proteins were transferred to a nitrocel-
lulose membrane using a wet transfer system (Bio-Rad,
Hercules, CA, USA) in transfer buffer (20% methanol,
0.1 mM Tris, 80 mM glycine) at 100 V for 90 min.
After blocking with 5% skim milk in TBST (Tris buff-
ered saline with Tween-20:- 8 g/L NaCl, 3 g/L Tris,
0.2 g/L KCl, 0.2% Tween-20, pH 7.4) for 1 h, blots
were probed with the primary antibody in 5% BSA/
TBST (anti-EphB4 H-200, Santa Cruz Biotechnology,
CA, USA) [9] or 5% skim milk/TBST (anti-ITGB8
ab80673, Abcam, Melbourne, VIC, Australia) overnight
at 4°C before incubation with horseradish peroxidase-
labelled secondary antibody anti-rabbit IgG (Sigma-
Aldrich, Castle Hill, NSW, Australia) in 5% skim
milk/TBST for 1 h at room temperature. Chemilumines-
cence was detected with Amersham™ ECL Plus Chemilu-
minescence kit (GE Healthcare, Silverwater, NSW,
Australia) following the manufacturer’s recommendation,
with a 10-30 sec exposure to SuperRX X-ray film (Fuji Film
Corporation, Japan).Migration assay
PC3 cells were seeded into 96-well Essen Bioscience
ImageLock plates (Essen BioSciences, Ann Arbor, MI,
USA) at 2 x 104 cells per well in four replicates and allowed
to proliferate for 24 h until they had formed a complete
monolayer. Cells were then transfected with ITGB8 siRNA
and allowed to grow for a further 24 h. The 96-well
WoundMaker (Essen Bioscience) was then used to create a
cell-free zone in the monolayer before the plates were
placed in the IncuCyte ZOOM (Essen Bioscience). Migra-
tion into the cell free zone was determined after 24 h and
quantified as relative wound density.
Invasion assay
Pre-coated growth-factor reduced Matrigel cell culture
inserts (24-well, pore size 8 μm; BD Biosciences, San
Jose, CA, USA) were seeded with serum-deprived 5 x 105
PC3 or 22Rv1 vector-only cells (22Rv1-VO) or 22Rv1
EphB4 over-expressing cells (22Rv1-B4) and transfected
with 100 nM ITGB8 siRNA or non-silencing AllStars
siRNA (Qiagen) in 0.1% FCS-containing medium. Medium
containing 10% FCS was used as chemo-attractant. Cells
were incubated for 22 h and cells that had not invaded were
removed from the upper chamber using a cotton swab.
Membranes were excised and mounted on glass slides with
ProLong Gold Antifade containing 4, 6-diamidino-2-
phenylindole, dihydrochloride (DAPI) (Life Technologies)
for visualization of the nuclei of cells that had invaded
through the Matrigel to the underside of the membrane.
Nuclei were counted in five random fields at 20 X magnifi-
cation using an Olympus epifluorescent microscope.
Adhesion assay
22Rv1-VO or –B4 cells, or their negative siRNA-control
or ITGB8 siRNA counterparts (1 x 105 cells), were
seeded into triplicate wells in a Vitronectin pre-coated
96 well adhesion assay plate, and an adhesion assay was
carried out according to the manufacturer’s instructions
(Merck Millipore, VIC, Australia).
Statistics
Statistical analysis was carried out using IBM SPSS
software package by employing the ANOVA analysis
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hoc test or Student’s t-test with p < 0.05 considered
significant.
Results
EPHB4 down-regulation results in differential gene
expression in LNCaP cells
In an effort to characterize the contribution of EphB4 to
regulating gene expression in prostate cancer, endogen-
ously EphB4-expressing LNCaP cells were transfected
with EPHB4 specific siRNAs and compared to negative
non-silencing siRNA cells using gene expression pro-
filing. Quantitation of Western immunoblots using
Image J confirmed knockdown of EPHB4 averaged
80.25 ± 8.96%. Using a 2-fold cut off, 260 genes were
up-regulated and 300 genes were found to be signifi-
cantly down-regulated when EPHB4 siRNA transfec-
tants were compared to the negative controls (Additional
file 1: Figure S1). Among the top ten down-regulated
genes were ITGB8 (29.4 fold), EIF4E3 (10.3 fold) and
SASH1 (6.8 fold) (Table 2). On the other hand, the top ten
up-regulated genes included MYO VI (5.7 fold), MMP12
(4.8 fold) and CYP11A1 (4.2 fold) (Table 3). Gene ontology
screening highlighted the biological process of cell adhe-
sion as being significantly de-regulated upon EPHB4
knockdown (Table 4). Amongst the genes involved in cell
adhesion were three integrin molecules that were de-
regulated (Table 4) including the top down-regulated gene,
ITGB8. We therefore chose to further investigate the rela-
tionship between EphB4 and those three integrins -
ITGB8, ITGA3 and ITGA10.
Integrins are significantly de-regulated in response to
changing EphB4 levels in prostate cancer cells
The microarray analysis revealed significant quantitative
changes in ITGB8 and ITGA10 (down-regulated) and
ITGA3 (up-regulated) (Figure 1A). To confirm these
data we employed real-time PCR analysis on a differentTable 2 Top ten significantly down-regulated genes in LNCaP
Fold change Gene symbol Description
-29.4 ITGB8 Integrin beta 8
-10.5 LOC100287846 Patched 1 pseudogene
-10.5 PROM1 Prominin 1/CD133
-10.3 EIF4E3 Eukaryotic translation initiation factor 4
-8.8 GBP3 Guanylate Binding Protein 3
-8.4 DOCK10 Dedicator of Cytokinesis 10
-7.9 C14orf38 Open reading frame
-6.9 TMC7 Transmembrane Channel-like 7
-6.8 SASH1 SAM and SH3 domain Containing 1
-5.8 FSD2 Fibronectin type III and SPRY domainset of LNCaP transfectants. Upon EPHB4 knockdown,
ITGB8 and ITGA10 were significantly down-regulated
(Figure 1B). ITGA3 however, was unchanged (Figure 1B).
Knockdown of EPHB4 with two different siRNAs also
resulted in a reduction of integrin β8 protein expression
(Figure 1C), confirming the results seen at the gene
level. Conversely, to investigate whether EphB4 over-
expression would result in a parallel increase in ITGB8
expression, and to ensure that these data were not due
to siRNA off-target effects, the expression of ITGB8 in
stable 22Rv1-EphB4 over-expressing cells was also deter-
mined using qRT-PCR and compared with 22Rv1 cells
containing the empty vector (22Rv1-VO). EphB4 over-
expression resulted in a significant 2.5 fold increase in
ITGB8 gene levels, but no significant effect was seen on
ITGA3 or ITGA10 expression (Figure 1D). Again, the in-
crease in gene expression of ITGB8 correlated with an
increase in protein level (Figure 1E). Together, these data
suggest that EPHB4 and ITGB8 are co-regulated in pros-
tate cancer cells. As integrin β8 has only one known het-
erodimer partner, integrin αV (ITGAV) [10], we also
sought to determine whether over-expression of EphB4
increases the expression of this integrin subunit. EPHB4
overexpression in 22Rv1 cells significantly increased
ITGAV gene expression by 1.7 fold (Figure 1F) suggest-
ing an overall increase in the integrin αvβ8 heterodimer
complex.
Knockdown of ITGB8 suppresses migration and invasion
in prostate cancer cells
Integrin β8 has been implicated in tumor cell invasive-
ness [11]. To analyse functional effects of integrin β8 in
prostate cancer cells, we employed siRNA knockdown.
In PC-3 cells, ITGB8 knockdown resulted in a 70% de-
crease in ITGB8 mRNA (Figure 2A). PC-3 cells trans-
fected with ITGB8-targeted siRNA showed a significant
decrease in in vitro wound healing migration and in
Matrigel invasion, when compared with PC-3 cellscells after EPHB4 siRNA knockdown
Function
Cell-cell and cell-extracellular matrix interactions
Uncharacterized
Transmembrane glycoprotein, stem cell marker
E family member 3 Recruits mRNA to ribsosome
Binding of guanidine nucleotides
Guanine nucleotide exchange factor
Uncharacterized
Multi-pass membrane protein
Candidate tumour suppressor in breast cancer
containing 2 Uncharacterized
Table 3 Top ten significantly up-regulated genes in LNCaP cells after EPHB4 siRNA knockdown
Fold change Gene symbol Description Function
5.7 MYO6 Myosin VI Actin-based motor protein
4.8 MMP12 Matrix-metallopeptidase 12 Cleavage of extra-cellular matrix
4.4 LOC100131726 HCC-related HCC-C11_v3 Miscellaneous RNA
4.3 TDRD7 Tudor Domain containing 7 Component of cytoplasmic RNA granules
4.3 OSMR Oncostatin M receptor Type I cytokine receptor
4.3 APOBEC3H Apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3H
Antiretroviral mRNA editing enzyme
4.2 CYP11A1 Cytochrome P450, family 11, subfamily A, polypeptide 1 Conversion of cholesterol to pregnolone
4.2 LRRTM3 Leucine Rich Repeat Transmembrane Neuronal 3 Implicated in neuronal disorders
4.1 GCOM1 GRINL1A complex locus 1 Read-through transcription between the MYZAP
(myocardial zonula adherens protein) and POLR2M
(polymerase (RNA) II (DNA directed) polypeptide M
3.9 TBC1D8B TBC1 domain family, member 8B Uncharacterized
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thermore, transfection of 22Rv1-VO and 22Rv1-B4 cells
with the ITGB8 siRNA resulted in a significant decrease
in Matrigel invasion (Figure 2D). There was no signifi-
cant difference in the adhesion to vitronectin of 22Rv1-
VO or 22Rv1–B4 cells transfected with ITGB8 siRNA
(Figure 2E). Together, these results highlight that integ-
rin β8 plays an important role in prostate cancer cell
migration and invasion in both endogenous and exogen-
ously over-expressing EphB4 cell models.
Correlation between ITGB8 and EPHB4 expression levels
To investigate whether there is a correlation between
ITGB8 and EPHB4 expression in different prostate can-
cer cells representing different stages of the disease, sev-
eral cell lines were subjected to RT-PCR (Figure 3A). All
prostate cell lines tested expressed EPHB4 as expected
[5,7]. ITGB8 was most highly expressed in PC-3 and
DU145 cells, followed by BPH-1 and LNCaP cells. The
metastatic subclonal line C4-2B derived from LNCaP
cells [12] showed no ITGB8 mRNA expression. To fur-
ther assess whether ITGB8 expression could be indica-
tive of clinical disease progression we surveyed the
Oncomine database. Analysis of the prostate cancer pro-
gression study conducted by Tomlins et al. [13] revealed
that in benign samples both EPHB4 and ITGB8 are
expressed at a low level and this increases dramatically
and significantly in prostatic intraepithelial neoplasiaTable 4 Significantly enriched gene ontology process in
LNCaP cells after EPHB4 siRNA knockdown
GO biological process Genes involved
Cell adhesion: ACHE; CD34; CDH19; CLDN10; CNTN6; COL5A1;
DLC1; DSC1; DSCAM; FEZ1; FRAS1; ITGA10; ITGA3;
ITGB8; JAM2; LAMA4; MTSS1; NELL2; NLGN3;
NRCAM; PKD2; STAB2; TGFBI; TNC; TNF; VCL
GO:0007155(PIN) (ITGB8: 9.5 fold, p = 1.24 x 10-4 and EPHB4 2.9
fold, p = 0.001), the precursor for prostate carcinoma
[14]. In carcinoma samples the expression of both genes
is elevated, with EPHB4 being significantly up-regulated
in comparison to benign tissue samples, but expression
of both ITGB8 and EPHB4 is much lower than in PIN
tissues. Metastatic samples show expression levels simi-
lar to benign tissue for both EPHB4 and ITGB8. These
results indicate that EPHB4 and ITGB8 are concurrently
up-regulated in PIN and their expression is progressively
lowered with disease advancement. This suggests that
both genes may play a role in the onset of prostate
cancer.
Discussion
We have recently shown that EphB4 over-expression
leads to a more aggressive phenotype in prostate cancer
cells [2]. In this study we set out to investigate the gene
expression changes that occurred when EPHB4 was
knocked down in LNCaP prostate cancer cells that are
endogenously over-expressing EphB4. Microarray ana-
lysis revealed a set of three integrin subunits (α3, α10
and β8) that were de-regulated upon siRNA knockdown
of EPHB4 and qRT-PCR validated two of these (α10 and
β8). Over-expression of EPHB4 led to concomitant and
parallel changes in expression and protein levels of
ITGB8 but not the other two integrins. In keratinocytes,
it has been shown that EphB2-induced reverse signaling
down-regulated integrin expression, demonstrating that
in other cell contexts other Eph receptors also have the
ability to influence integrin expression [15]. Integrins are
a family of transmembrane receptors which are primarily
involved in cell-extracellular matrix (ECM) adhesion as
well as cell-cell interactions. By connecting the actin
cytoskeleton to the ECM, integrins are able to regulate
attachment, cytoskeletal organization, mechano-sensing,
Figure 1 Integrins are significantly de-regulated in response to changing EphB4 levels in prostate cancer cells. A) Relative gene expression of
EPHB4, ITGA3, ITGA10 and ITGB8 after siRNA knockdown of EPHB4 in LNCaP cells as identified on the cDNA microarray, compared to control negative
siRNA. Dotted line indicates normalized level of negative siRNA control. B) Relative gene expression normalized to GAPDH of EPHB4, ITGA3, ITGA10 and
ITGB8 after siRNA knockdown of EPHB4 in LNCaP cells as determined by qRT-PCR (independent experiments from results shown in A). Dotted line
indicates normalized level of negative siRNA control. C) Western blotting analysis showing integrin β8 and EphB4 protein levels in LNCaP cells that have
been transfected with two different siRNAs (#2 and #5) targeting EPHB4. GAPDH was used to normalize for loading. D) Relative gene expression of
ITGA3, ITGA10 and ITGB8, normalized to GAPDH, in stably over-expressing 22Rv1-B4 cells as determined by qRT-PCR. Dotted line indicates normalized
level of negative siRNA control. E) Western blotting analysis showing integrin β8 and EphB4 protein levels in 22Rv1-B4 over-expressing prostate cancer
cells. GAPDH was used as a loading control. F) Relative gene expression of ITGAV in stably over-expressing 22Rv1-B4 compared to VO (vector only) cells
as determined by qRT-PCR. QRT-PCR experiments were carried out in triplicate and with three biological replicates. Western blotting experiments were
carried out three times and representative cropped blots are shown. Graphs are presented with ± SD. *** p < 0.005, ** p < 0.01, * p < 0.05.
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[16]. Through their several roles, integrins have been
found to be involved in a range of pathological processes
including tumor angiogenesis and metastasis [17,18].
There is evidence that Eph/ephrin signaling can influ-
ence integrin clustering and in some cases, inhibit integrin
downstream signaling [19,20]. Furthermore, ephrin-A1 andEphA2 have both been shown to co-localize with integrin
α3 [20-22]. In breast cancer cell lines, EphB4 exogenous
overexpression reduces integrin β1 expression resulting in
increased migration in a ligand-independent manner [23].
In the current study, validation experiments confirmed that
ITGB8 was significantly down-regulated when EPHB4 was
knocked down and moreover, was also up-regulated when
Figure 2 Knockdown of ITGB8 results in reduced metastatic potential in prostate cancer cells. A) Quantitative real-time PCR was carried
out to determine knockdown levels of siRNA against ITGB8. 100 nM negative non-silencing or ITGB8 targeting siRNA were transiently transfected
into PC-3 cells. RNA was isolated 48 h after transfection, transcribed into cDNA and analyzed for gene expression. ITGB8 expression is reduced by
approximately 60-70%. B) PC-3 cells were transiently transfected with 100 nM negative non-silencing (neg si) or ITGB8 targeting siRNA (β8 si) and
24 h later a scratch wound was applied using the IncuCyte (Essen Bioscience) system and migration was monitored for a further 24 h. Cell migration
was reduced following knockdown of ITGB8. C) PC-3 cells were transiently transfected with 100 nM negative non-silencing (neg si) or ITGB8 targeting
siRNA (β8 si) and subjected to a Matrigel transwell invasion assay. After 22 h of incubation, invaded cells were stained and counted. Cell invasion was
reduced following knockdown of ITGB8. D) 22Rv1-VO (vector only) or 22Rv1–B4 (EphB4 over-expressing) cells were transiently transfected with 100 nM
siRNA against ITGB8 (β8 si) or negative non-silencing siRNA (neg si). An invasion assay was carried out using the Matrigel invasion system and cells were
allowed to invade for 22 h. Cells containing the ITGB8 siRNA showed significantly reduced ability to invade. E) 22Rv1-VO (vector only) or 22Rv1–B4
(EphB4 over-expressing) cells were transiently transfected with siRNA against ITGB8 (β8 si) or negative non-silencing siRNA (neg si) and subjected to an
adhesion assay to vitronectin. No significant changes were seen. n = 3 * p < 0.01 vs VO negative; # p < 0.001 vs B4 negative.
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This suggests that EPHB4 and ITGB8 are potentially
transcriptionally co-regulated. In terms of transcrip-
tional regulation, the ITGB8 promotor contains SP and
CRE binding motifs and is regulated by SP1, SP3 and
an AP-1 complex [24]. EPHB4 on the other hand has
been shown to be transcriptionally regulated by HoxA9
in endothelial cells [25], but no information is available
about the transcription factors involved in regulating
expression of EPHB4 in cancer cells. It would beinteresting to investigate whether the transcription fac-
tors of the SP family can also influence EPHB4 expres-
sion in prostate cancer and thus be responsible for co-
regulating ITGB8 and EPHB4.
Although only limited information is available about
the role of integrin β8 in cancer it has been identified as
up-regulated in several cancers including head and neck
cancer, hepatocellular carcinoma, some ovarian cancer
and melanoma cell lines as well as primary non-small
lung cancer samples and brain metastases from several
Figure 3 Integrin expression levels across disease progression.
A) cDNA from several different prostate-derived cell lines was analyzed
using semi-quantitative RT-PCR. GAPDH amplification was used as a
loading control. B) Gene expression omnibus dataset GDS3289
investigating prostate cancer progression in LCM-captured clinical
samples was interrogated for EPHB4 and ITGB8 expression using the
Oncomine clinical database (www.oncomine.org). Both genes are
significantly elevated in prostatic intraepithelial neoplasia (PIN) and
EPHB4 is significantly upregulated in carcinoma samples compared to
benign. * p < 0.001, mets =metastatic disease.
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been identified as a member of a six-gene expression
signature biomarker predicting lung metastasis from
breast cancer [29]. In glioblastoma specimens, there
appears to be a correlation between low integrin β8
expression and highly angiogenic, but poorly invasive
tumors; as well as high integrin β8 expression in low
angiogenic and highly invasive tumors (17). This im-
plies that integrin β8 is involved in differential con-
trol of angiogenesis versus tumor cell invasion in
glioblastomas. On the other hand, integrin β8 has
been shown to be growth inhibitory in lung cancer
cells, yet it is also playing a fundamental role in lung
cancer metastasis indicating that this integrin func-
tions in a complex manner in cancer presumably de-
pending on tissue and progression context [30-32].
As the expression of integrin β8 has been found to be in-
creased in metastases from various tumors, includingbreast and lung, we speculated that integrin β8 could also
play a role in prostate cancer cell migration and invasion
and we show that silencing of ITGB8 reduces cell motility
[28,29]. In highly invasive glioblastoma tumors, high
levels of integrin β8 cooperate with Rho proteins to drive
invasion [11]. Eph receptors are also able to activate the
Rho pathway to regulate cancer cell migration [33] and
thus it is possible that EphB4 and integrin β8 work co-
operatively to control cell motility.
By interrogating the Oncomine database we have iden-
tified ITGB8 as being up-regulated in PIN, the precursor
to prostate cancer which is puzzling considering its role
in metastases. It is possible that integrin β8 is able to im-
pact on different stages of tumor development in differ-
ent cell populations. In established prostate cancer cell
lines we demonstrate that integrin β8 plays a vital role in
migration and invasion. These results are in agreement
with previous reports describing similar findings in lung
cancer and glioblastoma [11,31].
Integrin β8 has been shown to only heterodimerise
with the integrin αv subunit and this heterodimer binds
to vitronectin [10]. We show here that the αv subunit
expression also increases in stably EphB4 over-
expressing prostate cancer cells, but no effect on adhe-
sion to vitronectin was seen. Interestingly, transforming
growth factor β (TGF-β) has been identified as the only
physiologically relevant ligand for integrin αvβ8 and acti-
vation of matrix-bound latent TGF-β by integrin αvβ8
results in activation of TGF-β signaling and remodeling
of human airway fibroblasts [34]. TGF-β is a well-known
cytokine with a variety of physiological functions such as
proliferation, differentiation and immune response and
in addition it plays a major role in cancer progression by
inducing epithelial-to-mesenchymal transition (EMT) in
prostate cancer and promoting metastasis to the bone,
the final step in prostate cancer progression [35,36]. In
our array data TGFB1 was also found to be significantly
upregulated by 2-fold (data not shown). This could indi-
cate that EPHB4, ITGB8 and TGFB1 are intrinsically
regulated in prostate cancer cells, therefore contributing
to cancer progression and metastasis through the
process of EMT. However, expression analysis of the
EMT markers E-cadherin and Snail did not show any
significant changes in PC-3 cells transfected with ITGB8
siRNA (data not shown). Changes in E-cadherin and
Snail expression have been reported in lung cancer cells
where ITGB8 was silenced [31].
Cilengitide, a selective antagonist of αvβ3 and vβ5
integrins, is currently in clinical trials for a variety of
solid tumors, but so far the results are modest [37-39].
In prostate cancer, no clinical effect was seen [40]. Tar-
geting the αvβ8 integrin in combination with EphB4
targeted therapies may represent a future avenue for
prostate cancer therapy.
Mertens-Walker et al. BMC Cancer  (2015) 15:164 Page 9 of 10Conclusions
Alteration of EphB4 levels (through knockdown or over-
expression) concurrently, and in a similar manner, alters
the levels of integrin β8. The high level of expression of
both EPHB4 and ITGB8 in clinical PIN samples suggests
that their increased expression is an early event in the
development of prostate cancer. This also identifies a
new mechanism for EphB4 function in prostate cancer
through the regulation of ITGB8, which our results
show can contribute to prostate cancer cell motility. Tar-
geting both EphB4 and integrin β8 may provide new
options for treating prostate cancer.
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